PLRX Pliant Therapeutics, Inc.
$0.84▼ -0.78%
Healthcare
Other
Volume 16.5K
Avg Volume (10D) 432.5K
Key Metrics & Fundamentals
Market Cap
$52.20M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.83 - 1.83
% vs 50 MA
-20.20%
% vs 200 MA
-27.40%
RSI-14
30.9
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.10
Free Cash Flow
-$12.80M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$22.12M
COGS
–
Operating Exp
$23.86M
Operating Income
-$23.86M
EBIT
-$23.86M
Pretax Income
-$22.37M
Net Income
-$22.37M
EPS (Diluted)
-0.36
Price & Volume History
Loading chart…
Recent News
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
GlobeNewswire · Oct 20, 2026 8:30 AM ET
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
GlobeNewswire · Oct 19, 2026 4:05 PM ET
Pliant Therapeutics Appoints David Raben as Chief Medical Officer
MT Newswires · Sep 30, 2026 5:28 PM ET
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
GlobeNewswire · Sep 30, 2026 4:10 PM ET
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
GlobeNewswire · Aug 18, 2026 8:30 AM ET
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
GlobeNewswire · Aug 11, 2026 4:05 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See PLRX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.